Application of recombinant protein rcFAM3A in preparation of medicine for preventing and / or treating renal fibrosis

Through the overexpression of the recombinant protein rcFAM3A, the problem of insufficient treatment methods for renal fibrosis was solved, and the damage and fibrosis of renal tubular epithelial cells was significantly reduced, providing a new treatment method for renal fibrosis, showing its intravenous fibers The key role in transformation.

CN118976098AActive Publication Date: 2024-11-19THE SECOND XIANGYA HOSPITAL OF CENT SOUTH UNIV
View PDF 8 Cites 0 Cited by

Patent Information

Application Number
CN202411288167.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2024-08-01
Filing Date
2024-09-14
Publication Date
2024-11-19
Estimated Expiration
2044-09-14

Smart Images

  • Figure CN118976098A_ABST
    Figure CN118976098A_ABST
Patent Text Reader

Abstract

The invention relates to the field of biological medicine, in particular to application of recombinant protein rcFAM3A in preparation of medicine for preventing and / or treating renal fibrosis. Innovative research shows that the recombinant protein rcFAM3A can induce FAM3A overexpression, so that the recombinant protein rcFAM3A can be used as a medicine for effectively preventing and / or treating renal fibrosis.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of medicines, and in particular to the field of medicines for treating renal fibrosis. Background Art

[0002] Renal fibrosis is a multifactorial progressive disease involving multiple cell types from both the kidney and extrarenal sources, including four main cell types involved in the progression of chronic kidney disease (CKD): tubular epithelial cells (TECs), myofibroblasts, endothelial cells, and immune cells. Different cell types play complex, unique, and interconnected roles. TECs are the main component of the kidney's response to injury and repair, and a comprehensive characterization of the complex mechanisms and signaling mediators of renal fibrosis will help to propose new therapeutic approaches.

[0003] Renal fibrosis is an inevitable consequence of almost all forms of progressive CKD. [1] However, there are currently limited effective treatments that can prevent or reverse renal fibrosis. [2] , mainly in the areas of small drug molecules and biological molecules.

[0004] For example, the U.S. patent document with publication number US11976111B2 discloses an ActRIIa and ALK4 polypeptide for treating renal fibrosis, inflammation and injury. The Chinese patent document with publication number CN112423742A discloses a use of Actarit in preventing or treating renal fibrosis or renal disease of a subject. The use of compound EP9 with publication number CN115844884A in the preparation of a drug for treating diabetic nephropathy and renal fibrosis. The Chinese patent document with publication number CN111479587A discloses the use of a FXIIa inhibitor in treating renal fibrosis and / or chronic kidney disease.

[0005] In summary, although the existing technologies have many treatment methods and means for renal fibrosis, its treatment methods still need to be further expanded.

[0006] References:

[0007] [1].Duffield,JS,Cellular and molecular mechanisms in kidneyfibrosis.J Clin Invest,2014.124(6):p.2299-306.

[0008] [2].Ruiz-Ortega,M.,et al.,Targeting the progression of chronic kidneydisease.Nat Rev Nephrol, 2020.16(5):p.269-288. Summary of the invention

[0009] The first object of the present invention is to provide a use of a recombinant protein rcFAM3A in the preparation of a drug for preventing and / or treating renal fibrosis.

[0010] The second object of the present invention is to provide a drug for preventing and / or treating renal fibrosis comprising the recombinant protein rcFAM3A.

[0011] A use of a recombinant protein rcFAM3A in preparing a drug for preventing and / or treating renal fibrosis.

[0012] The innovative research of the present invention shows that the recombinant protein rcFAM3A can induce FAM3A overexpression, and FAM3A overexpression can effectively prevent and / or treat renal fibrosis, and can be used as a new prevention and treatment method for renal fibrosis.

[0013] In the present invention, the amino acid sequence of the recombinant protein rcFAM3A is MRLAGPLRIVVLVVSVGVTWIVVSILLGGPGSGFPRIQQLFTSPESSVTAAPRARKYKCGLPQPCPEEHLAFRVVSGAANVIGPKICLEDKMLMSSVKDNVGRGLNIALVNGVSGELIEARAFDMWAGDVNDLLKFIRPLHEGTLVFVASYDDPATKMNEETRKLFSELGSRNAKELAFRDSWVFVGAKGVQNKSPFEQHVKNSKHSNKYEGWPEALEMEGCIPRRSTASTRTRPLEQKLISEEDLAANDILDYKDDDDKV.

[0014] In the present invention, the recombinant protein rcFAM3A is the recombinant protein rcFAM3A produced by ORIGENE with the product number TP303495.

[0015] In the present invention, the recombinant protein rcFAM3A is prepared to prevent and / or treat renal fibrosis induced by unilateral ureteral ligation or ischemia-reperfusion.

[0016] In the present invention, the recombinant protein rcFAM3A is combined with a pharmaceutically acceptable excipient to prepare a drug for preventing and / or treating renal fibrosis.

[0017] In the present invention, the recombinant protein rcFAM3A is used to prepare a pharmaceutically acceptable dosage form for preventing and / or treating renal fibrosis.

[0018] In the present invention, the drug dosage form is an injection preparation.

[0019] The present invention also provides a drug for preventing and / or treating renal fibrosis, which comprises a pharmaceutically effective amount of the recombinant protein rcFAM3A described in the application.

[0020] The drug for preventing and / or treating renal fibrosis of the present invention further comprises a pharmaceutically acceptable excipient.

[0021] The drug for preventing and / or treating renal fibrosis has a pharmaceutically acceptable preparation, preferably an injectable preparation.

[0022] The present study showed that FAM3A is mainly localized in the proximal tubular epithelial cells of the kidney, and FMA3A expression is reduced in damaged tubules. The expression level of FAM3A is not only negatively correlated with the degree of renal fibrosis in CKD patients, but also positively correlated with the renal function eGFR level in CKD patients. Treatment with recombinant protein rcFAM3A significantly alleviated the renal fibrosis model caused by unilateral ureteral ligation and ischemia-reperfusion, as well as TGF-β1-induced epithelial-mesenchymal transition of tubular epithelial cells and deposition of extracellular matrix. The above research results show that FMA3A plays a key role in the progression of renal fibrosis, and overexpression of FAM3A may be a potential new therapy for delaying renal fibrosis.

[0023] In the present invention, in terms of animal models, exogenous supplementation of recombinant protein rcFAM3A can alleviate renal fibrosis caused by UUO and UIR models, which is specifically manifested in that rcFAM3A significantly alleviates the damage and fibrotic lesions of renal tubular epithelial cells, and the expression of FN and α-SMA in the rcFAM3A+UUO group and the rcFAM3A+UIR group is significantly reduced, and the expression of E-cadherin is significantly increased. The recombinant protein rcFAM3A significantly reduces the mRNA levels of renal injury marker molecules NGAL and KIM1, and inhibits the mRNA levels of fibrosis indicators such as TGF-β1, type I collagen or type IV collagen. In terms of cell experiments, the application of recombinant protein rcFAM3A can reduce the expression of FN, α-SMA and Vimentin in proximal renal tubular epithelial cells induced by TGF-β1. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] Figure 1The expression changes and cellular localization of FAM3A in the kidneys of CKD patients and animal models (sham is the sham operation group, UUO is the unilateral ureteral ligation model group, and UIR is the unilateral renal ischemia-reperfusion model group);

[0025] Figure 2 This is a diagram showing the effect of recombinant protein rcFAM3A on renal fibrosis caused by UUO model;

[0026] Figure 3 This is a diagram showing the effect of recombinant protein rcFAM3A on renal fibrosis caused by the UIR model;

[0027] Figure 4 This figure shows the effect of recombinant protein rcFAM3A on TGF-β1-induced proximal tubular epithelial cell fibrosis. DETAILED DESCRIPTION

[0028] The present invention is described in detail below through specific examples. Unless otherwise specified, the reagents used in the present invention are all commercially available reagents. Mouse kidney proximal tubular epithelial cells (mPTECs) were provided by the Department of Nephrology, the Third Hospital of Hebei Medical University.

[0029] The experimental methods and materials used in the following examples are as follows:

[0030] Construction of animal models: Two renal fibrosis models, unilateral ureteral ligation (UUO) and unilateral renal ischemia-reperfusion (UIR), were established.

[0031] (1) Eight-week-old male C57BL / 6J mice from the Experimental Animal Center of Xiangya School of Medicine, Central South University were randomly divided into four groups (sham operation + PBS group, n = 6; sham operation + rcFAM3A group, n = 6; UUO + PBS group, n = 6; UUO + rcFAM3A group, n = 6). In order to achieve overexpression of FAM3A, mice were injected with rcFAM3A (0.2 μg / mouse) through the tail vein 7 days before surgery, and the control group was injected with an equal amount of PBS. Then, the UUO surgery was performed as follows: the mice were first anesthetized with 1% sodium pentobarbital, and the skin and peritoneum were cut along the midline of the abdomen to fully expose the left ureter area. The upper and lower poles of the ureter were ligated with 4.0 surgical sutures, the middle ureter was cut, and finally the wound was sutured in sequence. Except for ureteral ligation, the rest of the steps in the sham operation group were the same. rcFAM3A or PBS was injected into the tail vein on the day of surgery and the third day after surgery. The mice were killed on the 7th day after surgery, and serum and kidney tissue specimens were collected for subsequent experiments.

[0032] (2) 8-week-old male C57BL / 6J mice were randomly divided into 4 groups (sham operation + PBS group, n = 6; sham operation + rcFAM3A group, n = 6; UIR + PBS group, n = 6; UIR + rcFAM3A group, n = 6). In order to achieve overexpression of FAM3A, mice were injected with rcFAM3A (0.2 μg / mouse) through the tail vein 7 days before surgery, and the control group was injected with an equal amount of PBS, and then UIR surgery was performed. The steps are as follows: first, the mice were anesthetized with 1% sodium pentobarbital, and the skin and muscle layer were cut along the left rib margin to fully expose the left kidney. The left renal artery was clamped with an artery clamp, and the mice were placed on a 37°C constant temperature electric blanket. When the timer reached 35 minutes, the artery clamp was released and the wound was sutured in turn. The rest of the steps were the same as those in the sham operation group except for the clamping of the left renal artery. rcFAM3A or PBS was injected into the tail vein on the day of surgery, the 7th day after surgery, and the 14th day after surgery. The mice were killed on the 21st day after surgery, and serum and kidney tissue samples were collected for subsequent experiments. All experiments were approved by the Medical Ethics Committee of Central South University.

[0033] (3) Kidney pathological staining analysis: The kidney specimens were fixed in 4% paraformaldehyde for 24 hours, embedded in paraffin blocks with gradient ethanol and xylene, made into paraffin sections (4 μm), and then dewaxed to water. PAS staining, Masson staining, and Sirius red staining were used to evaluate the degree of tubular damage and renal interstitial fibrosis.

[0034] (4) Immunohistochemical staining: After paraffin sections were dewaxed and hydrated, 3% hydrogen peroxide was added to block endogenous peroxidase, placed in a microwave oven for antigen retrieval, blocked with 5% BSA for 1 hour, and incubated with FAM3A (1:200) and α-SMA (1:800) antibodies at 4°C overnight. The next day, the secondary antibody was incubated at room temperature for 30 minutes, DAB was used for color development, hematoxylin was used for nuclei, and the sections were sealed with neutral resin. Image analysis and statistical quantification were performed using Image J.

[0035] (5) Immunofluorescence staining: After paraffin sections were dewaxed and hydrated, they were placed in a microwave oven for antigen retrieval, blocked with 5% BSA for 1 hour, and incubated with FAM3A (1:200), LTL (1:100), KIM-1 (1:400), and E-cadherin (1:400) antibodies at 4°C overnight. The next day, the secondary antibody was incubated at room temperature for 60 minutes and the sections were mounted with DAPI. Image analysis and statistical quantification were performed using Image J.

[0036] (6) Cell culture: Mouse proximal tubule epithelial cells (mPTECs) were grown in a DMEM high-glucose medium containing 10% FBS in an incubator at 37°C and 5% CO2. When the cells grew to 70-80% confluence, they were starved with serum-free medium for 12 hours to achieve synchronization, and then treated with 10 ng / ml TGF-β1 or 200 ng / ml recombinant protein rcFAM3A for 24 hours.

[0037] (7) qRT-PCR: RNA from kidney tissue or cells was extracted by Trizol-chloroform-isopropanol. 1 μg RNA was reverse transcribed into cDNA using RT mix (Acori Biotech). Real-time PCR was performed on a LightCycler 96 instrument (Roche, Germany) using SYBR Green PCR Master Mix (Yisheng). GAPDH was used as an internal reference, and the relative value was calculated using the ΔΔCt method.

[0038] (8) Western blot: Tissues or cells were fully lysed with RIPA protein lysis buffer containing 1% phosphatase and protease inhibitors, protein concentration was measured by BCA method, and the samples were heated in a metal bath for denaturation. Protein samples were subjected to electrophoresis, transfer and blocking, and then incubated with primary antibodies FAM3A (1:1000), FN (1:1000), α-SMA (1:1000), E-cadherin (1:20000), Vimentin (1:20000) and Tubulin (1:5000) at 4°C overnight. The next day, secondary antibodies were incubated at room temperature for 1 hour, and bands were developed using a developer, and bands were quantified and analyzed using Image J.

[0039] (9) Cell immunofluorescence staining: After the cells were treated, they were washed with PBS, fixed with 4% paraformaldehyde, permeabilized with 0.3% TritonX-100, and blocked with 5% BSA. Primary antibodies α-SMA (1:400) and Vimentin (1:400) were added dropwise to a 12-well plate, incubated overnight at 4°C, incubated with secondary antibodies at room temperature for 1 hour, washed with PBS, mounted with DAPI, and observed and photographed under a laser confocal microscope.

[0040] (10) Statistical analysis: The experimental data are expressed as mean ± SEM. The two-tailed Student t test was used for comparison between two groups, and one-way analysis of variance was used for comparison between multiple groups. P < 0.05 was defined as significant. GraphPad Prism 8 software was used to draw statistical graphs.

[0041] By including renal biopsy specimens from CKD patients and adjacent normal controls, immunohistochemistry showed that FAM3A protein was significantly reduced in the kidneys of CKD patients and was negatively correlated with the degree of renal fibrosis ( Figure 1ab); Nephroseq database showed that the expression of FAM3A in kidney was positively correlated with the renal function eGFR level of CKD patients ( Figure 1 c); Western blot results showed that the FAM3A protein level was significantly decreased on days 3, 7, and 14 of the UUO model and on day 21 of the UIR model ( Figure 1 d), Immunofluorescence showed that FAM3A was mainly localized in the proximal tubular epithelial cells of mouse kidneys ( Figure 1 e), and its expression level was significantly reduced in renal tubules of renal injury ( Figure 1 f), suggesting that down-regulation of FAM3A expression is closely related to the degree of renal injury and interstitial fibrosis, and may be an important molecule for preventing and treating CKD progression.

[0042] To evaluate the effect of overexpression of FAM3A on renal fibrosis, we injected recombinant protein rcFAM3A (0.2 μg / mouse) into mice via tail vein, which significantly increased the expression of FAM3A in their kidneys ( Figure 2 ab and Figure 3 ab); Western blot results showed that compared with the UUO group, the FN protein in the rcFAM3A+UUO group was significantly reduced, while the E-cadherin protein was significantly increased ( Figure 2 c); In addition, the expressions of renal injury markers NGAL and KIM1 mRNA and fibrosis indicators TGF-β1 and collagen 4A mRNA in the rcFAM3A+UUO group were significantly decreased ( Figure 2 d). PAS and Masson pathological staining showed that the dilatation of renal tubules in the rcFAM3A+UUO group was improved, the shedding of brush border was reduced, the collagen deposition in the renal interstitium was reduced, and the fibrotic lesions were alleviated; immunohistochemistry showed that the epithelial-mesenchymal transition marker α-SMA was significantly reduced in the rcFAM3A+UUO group; immunofluorescence showed that the fluorescence intensity of the renal injury molecule KIM1 was weakened in the rcFAM3A+UUO group, while the fluorescence intensity of E-cadherin was enhanced ( Figure 2 e), indicating that overexpression of FAM3A has a certain protective effect on renal injury and fibrosis caused by UUO. In addition, in the UIR model, the application of recombinant protein cFAM3A can also alleviate renal injury and fibrosis caused by UIR ( Figure 3 ).

[0043] In in vitro cell experiments, the application of recombinant protein rcFAM3A can reduce the expression of FN, α-SMA and Vimentin proteins, which are indicators of renal tubular epithelial cell fibrosis induced by TGF-β1 ( Figure 4 ).

[0044] In summary, this application confirms through in vivo animal models and in vitro cell experimental data that the application of recombinant protein rcFAM3A treatment can significantly reduce renal fibrosis caused by unilateral ureteral obstruction, ischemia-reperfusion injury, and TGF-β1-induced fibrotic effects of renal tubular epithelial cells, indicating that FMA3A plays an important role in the progression of renal fibrosis, and overexpression of FMA3A is a potential new anti-renal fibrosis therapy.

Claims

1. Use of a recombinant protein rcFAM3A in the preparation of a drug for preventing and / or treating renal fibrosis.

2. Use of the recombinant protein rcFAM3A according to claim 1 in the preparation of a drug for preventing and / or treating renal fibrosis, characterized in that: The amino acid sequence of the recombinant protein rcFAM3A is MRLAGPLRIVVLVVSVGVTWIVVSILLGGPGSGFPRIQQLFTSPESSVTAAPRARKYKCGLPQPCPEEHLAFRVVSGAANVIGPKICLEDKMLMSSVKDNVGRGLNIALVNGVSGELIEARAFDMWAGDVNDLLKFIRPLHEGTLVFVASYDDPATKMNEETRKLFSELGSRNAKELAFRDSWVFVGAKGVQNKSPFEQHVKNSKHSNKYEGWPEALEMEGCIPRRSTASTRTRPLEQKLISEEDLAANDILDYKDDDDKV.

3. Use of the recombinant protein rcFAM3A according to claim 1 in the preparation of a drug for preventing and / or treating renal fibrosis, characterized in that: The recombinant protein rcFAM3A is the recombinant protein rcFAM3A produced by ORIGENE with the product number TP303495.

4. Use of the recombinant protein rcFAM3A according to any one of claims 1 to 3 in the preparation of a drug for preventing and / or treating renal fibrosis, characterized in that: The recombinant protein rcFAM3A is prepared to prevent and / or treat renal fibrosis induced by unilateral ureteral ligation and ischemia-reperfusion.

5. Use of the recombinant protein rcFAM3A according to claim 1 in the preparation of a drug for preventing and / or treating renal fibrosis, characterized in that: The recombinant protein rcFAM3A is combined with a pharmaceutically acceptable excipient to prepare a drug for preventing and / or treating renal fibrosis.

6. Use of the recombinant protein rcFAM3A according to claim 5 in the preparation of a drug for preventing and / or treating renal fibrosis, characterized in that: The recombinant protein rcFAM3A is used to prepare a pharmaceutically acceptable dosage form for preventing and / or treating renal fibrosis.

7. Use of the recombinant protein rcFAM3A according to claim 6 in the preparation of a drug for preventing and / or treating renal fibrosis, characterized in that: The drug dosage form is an injection preparation.

8. A drug for preventing and / or treating renal fibrosis, characterized in that: Comprising a pharmaceutically effective amount of the recombinant protein rcFAM3A described in any one of claims 1 to 7.

9. The drug for preventing and / or treating renal fibrosis according to claim 8, characterized in that: Also contains pharmaceutically acceptable excipients.

10. The drug for preventing and / or treating renal fibrosis according to claim 8, characterized in that: It has a pharmaceutically acceptable preparation, preferably an injectable preparation.

Citation Information

Patent Citations

  • Use of FXIIa-inhibitor in treatment of renal fibrosis and / or chronic kidney disease

    CN111479587A

  • The use of actarit in the prophylaxis or treatment of renal fibrosis or kidney disease

    CN112423742A

  • Application of compound EP9 in preparation of medicine for resisting renal fibrosis of diabetic nephropathy

    CN115844884A

  • ActRIIa and ALK4 polypeptides for treating kidney fibrosis, inflammation and injury

    US11976111B2

  • Application of micromolecule polypeptide KP-4 in preparation of medicine for treating renal fibrosis or chronic kidney disease

    CN117384257A